Loading
A phase 3 trial of pemetrexed and pembrolizumab in lung cancer, run by Hunan Province Tumor Hospital, now recruiting.
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors is a phase 3, interventional study registered as NCT05055908 by Hunan Province Tumor Hospital, with a registry enrolment figure of 12000 participants, started 2021-10-01 and due to reach its primary completion in 2025-07-01. Interventions recorded: Pemetrexed plus Pembrolizumab; Pembrolizumab; Pemetrexed. Conditions listed: Lung Cancer. Primary outcome: Correlation between Adverse events (AEs) and gene profile. Lung eligibility wording from the registry: "Histologically or cytologically confirmed lung cancer". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Lung cancer (all types), Pembrolizumab and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Pembrolizumab, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Pembrolizumab, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Pembrolizumab, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/